You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,837,994

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,837,994

Title:	Use of anti-IL-20 antibody for treating osteoporosis
Abstract:	Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.
Inventor(s):	Chang; Ming-Shi (Tainan, TW)
Assignee:	National Cheng Kung University (Tainan, TW)
Application Number:	12/246,715
Patent Claims:	1. A method of treating osteoporosis comprising administering to a subject in need thereof an effective amount of an anti-IL-20 antibody, wherein the antibody contains a V.sub.H region including all the complementarity-determining regions in the V.sub.H region of mAb 7E and a V.sub.L region including all the complementarity-determining regions in the V.sub.L region of mAb 7E, and wherein mAb 7E is produced by the hybridoma cell line deposited with the American Type Culture Collection as Deposit Number PTA-8687. 2. The method of claim 1, wherein the anti-IL-20 antibody is an antibody containing the V.sub.H and V.sub.L regions of mAb 7E. 3. The method of claim 2, wherein the anti-IL-20 antibody is mAb 7E. 4. The method of claim 2, wherein the anti-IL-20 antibody is a functional fragment of mAb 7E. 5. The method of claim 2, wherein the anti-IL-20 antibody is a Fab, F(ab').sub.2, single chain antibody or a chimeric antibody. 6. The method of claim 1, wherein the anti-IL-20 antibody is a humanized antibody. 7. The method of claim 1, further comprising administering to the subject an effective amount of etanercept. 8. The method of claim 7, wherein the anti-IL-20 antibody is a humanized antibody. 9. The method of claim 7, wherein the anti-IL-20 antibody is a chimeric antibody. 10. The method of claim 1, further comprising administration of a fusion protein containing human soluble TNF receptor and the Fc component of human immunoglobulin G1. 11. The method of claim 10, wherein the anti-IL-20 antibody is a humanized antibody. 12. The method of claim 10, wherein the anti-IL-20 antibody is a chimeric antibody.

Details for Patent 7,837,994

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.